Skip to content

Predicting ILD from Hypersensitivity Pneumonitis

Search Clinical Trials

Trial Objectives

Researchers believe they will be able to predict which patients with chronic Hypersensitivity Pneumonitis (HP) will develop interstitial lung disease (ILD) by looking at their genes and biomarkers in their blood. For this observational study, researchers will collect samples and data from participants with rapidly progressing HP and slowly progressing HP to look for patterns that can help predict the development of ILD and form specialized treatment plans.

Who Can Participate

Adults who have been diagnosed with Hypersensitivity Pneumonitis (HP).

Age: 18-90 Gender Any

Estimated Time Commitment

Clinic visits every 6 months over approximately 2 years (4 visits total)

Payment & Reimbursement

Payment Not Provided

Travel Reimbursement Not Available

Trial Contact

For more information, contact:

Elizabeth Del Real

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Investigator Initiated with funding from Boehringer Ingelheim

Principal Investigators

Evans Fernández

Evans Fernández, MD, MS


  • Tristan J. Huie

    Tristan J. Huie, MD

  • Rebecca C. Keith

    Rebecca C. Keith, MD

  • Lisa A. Maier

    Lisa A. Maier, MD, MSPH, FCCP

  • Michael P. Mohning

    Michael P. Mohning, MD

  • Joshua J. Solomon

    Joshua J. Solomon, MD

  • Zulma X. Yunt

    Zulma X. Yunt, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required